Product Name
NR4A3, siRNA
Full Product Name
NR4A3 siRNA (Rat)
Product Synonym Names
NOR1; Nuclear receptor subfamily 4 group A member 3; Neuron-derived orphan receptor 1/2; Nuclear hormone receptor NOR-1/NOR-2
Product Gene Name
NR4A3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P51179
Specificity
NR4A3 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat NR4A3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of NR4A3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
NR4A3 sirna
siRNA to inhibit NR4A3 expression using RNA interference
Applications Tested/Suitable for NR4A3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for NR4A3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_113816.1
[Other Products]
NCBI GenBank Nucleotide #
NM_031628.1
[Other Products]
UniProt Primary Accession #
P51179
[Other Products]
UniProt Secondary Accession #
Q2XPY2; Q63516; Q9QWQ3[Other Products]
UniProt Related Accession #
P51179[Other Products]
Molecular Weight
46,240 Da
NCBI Official Full Name
nuclear receptor subfamily 4 group A member 3
NCBI Official Synonym Full Names
nuclear receptor subfamily 4, group A, member 3
NCBI Official Symbol
Nr4a3 [Similar Products]
NCBI Official Synonym Symbols
NOR-2
[Similar Products]
NCBI Protein Information
nuclear receptor subfamily 4 group A member 3
UniProt Protein Name
Nuclear receptor subfamily 4 group A member 3
UniProt Synonym Protein Names
Neuron-derived orphan receptor 1/2; Nuclear hormone receptor NOR-1/NOR-2
Protein Family
Nuclear receptor subfamily
UniProt Gene Name
Nr4a3 [Similar Products]
UniProt Synonym Gene Names
Nor1 [Similar Products]
UniProt Entry Name
NR4A3_RAT
NCBI Summary for NR4A3
nuclear orphan receptor; involved in regulating transcription [RGD, Feb 2006]
UniProt Comments for NR4A3
NR4A3: Binds to the B1A response-element. Defects in NR4A3 are a cause of Ewing sarcoma (ES). A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors. A chromosomal aberration involving NR4A3 is found in patients with Erwing sarcoma. Translocation t(9;22)(q22-31;q11-12) with EWSR1. A chromosomal aberration involving NR4A3 is a cause of a form of extraskeletal myxoid chondrosarcomas (EMC). Translocation t(9;17)(q22;q11) with TAF2N. Belongs to the nuclear hormone receptor family. NR4 subfamily. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Oncoprotein; Nuclear receptor; DNA-binding
Cellular Component: transcription factor complex; nucleus
Molecular Function: ligand-dependent nuclear receptor activity; DNA binding; zinc ion binding; sequence-specific DNA binding; steroid hormone receptor activity
Biological Process: transcription from RNA polymerase II promoter; response to peptide hormone stimulus; axon guidance; organ regeneration; inner ear morphogenesis; intracellular receptor-mediated signaling pathway; transcription, DNA-dependent; hippocampus development; semicircular canal morphogenesis; positive regulation of cell cycle; mesoderm formation; response to hydrogen peroxide; vestibular reflex; ***** behavior; steroid hormone mediated signaling; positive regulation of transcription from RNA polymerase II promoter; negative regulation of neuron apoptosis; neuromuscular process controlling balance; negative regulation of apoptosis
Research Articles on NR4A3
1. mechanisms of NOR1 regulation
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
